![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » UK Trial to Test Anti-Inflammatory and Cancer Drugs as Possible COVID-19 Treatments
UK Trial to Test Anti-Inflammatory and Cancer Drugs as Possible COVID-19 Treatments
![UKflag.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/UKflag.jpg?t=1586293848&width=430)
Researchers at the Universities of Birmingham and Oxford have said they will test a series of new and existing medications as potential treatments for hospitalized COVID-19 patients, starting with two anti-inflammatory drugs.
Izana Biosciences’ namilumab and Celltrion Healthcare’s Remsima (infliximab) are the first drugs selected for the large Catalyst trial.
Namilumab is a human monoclonal antibody already in late-stage trials for treatment of rheumatoid arthritis and ankylosing spondylitis, while infliximab is an anti-tumor necrosis factor (TNF) therapy currently used as a treatment for inflammatory conditions, including eight autoimmune diseases.
Upcoming Events
-
18Jul
-
21Oct